Paper39768154
Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients.
Aubergeon L and 4 others. Cells, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients. Papers, record 39768154. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39768154
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lupus Erythematosus, Systemic | Major topic |
| Receptors, Immunologic | Major topic |
| Humans | |
| Female | |
| Adult | |
| Male | |
| Memory B Cells | |
| Middle Aged | |
| Receptors, Tumor Necrosis Factor, Member 14 | |
| Case-Control Studies |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22129255 | Systemic lupus erythematosus. | N Engl J Med | 2011 | https://conductscience.org/library/papers/22129255 | PubMed |
| 2 | 30833946 | The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis. | Front Immunol | 2019 | https://conductscience.org/library/papers/30833946 | PubMed |
| 3 | 34899718 | High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease. | Front Immunol | 2021 | https://conductscience.org/library/papers/34899718 | PubMed |
| 4 | 35464461 | Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity. | Front Immunol | 2022 | https://conductscience.org/library/papers/35464461 | PubMed |
| 5 | 28886017 | B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. | PLoS One | 2017 | https://conductscience.org/library/papers/28886017 | PubMed |
| 6 | 33028979 | Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. | Nat Immunol | 2020 | https://conductscience.org/library/papers/33028979 | PubMed |
| 7 | 37300833 | Extrafollicular IgD-CD27-CXCR5-CD11c- DN3 B cells infiltrate inflamed tissues in autoimmune fibrosis and in severe COVID-19. | Cell Rep | 2023 | https://conductscience.org/library/papers/37300833 | PubMed |
| 8 | 15701725 | Identification and characterization of circulating human transitional B cells. | Blood | 2005 | https://conductscience.org/library/papers/15701725 | PubMed |
| 9 | 11067960 | Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. | J Immunol | 2000 | https://conductscience.org/library/papers/11067960 | PubMed |
| 10 | 22903545 | CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. | J Mol Med (Berl) | 2013 | https://conductscience.org/library/papers/22903545 | PubMed |
| 11 | 35420627 | SARS-CoV-2 infection relaxes peripheral B cell tolerance. | J Exp Med | 2022 | https://conductscience.org/library/papers/35420627 | PubMed |
| 12 | 19155498 | B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. | J Immunol | 2009 | https://conductscience.org/library/papers/19155498 | PubMed |
| 13 | 36109639 | Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. | Nat Med | 2022 | https://conductscience.org/library/papers/36109639 | PubMed |
| 14 | 39444662 | Extrafollicular CD19lowCXCR5-CD11c- double negative 3 (DN3) B cells are significantly associated with disease activity in females with systemic lupus erythematosus. | J Transl Autoimmun | 2024 | https://conductscience.org/library/papers/39444662 | PubMed |
| 15 | 38676311 | B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis. | Clin Pharmacol Ther | 2024 | https://conductscience.org/library/papers/38676311 | PubMed |
| 16 | 8958217 | B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. | J Clin Invest | 1996 | https://conductscience.org/library/papers/8958217 | PubMed |
| 17 | 35537322 | The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases. | Cell Immunol | 2022 | https://conductscience.org/library/papers/35537322 | PubMed |
| 18 | 35507291 | Plasmablast-like Phenotype Among Antigen-Experienced CXCR5-CD19low B Cells in Systemic Lupus Erythematosus. | Arthritis Rheumatol | 2022 | https://conductscience.org/library/papers/35507291 | PubMed |
| 19 | 32775467 | Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients. | J Immunol Res | 2020 | https://conductscience.org/library/papers/32775467 | PubMed |
| 20 | 12796776 | BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. | Nat Immunol | 2003 | https://conductscience.org/library/papers/12796776 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41828562 | Early Marrow Microenvironment Immune Patterns After Hematopoietic Stem Cell Transplant in Pediatric Acute Lymphoblastic Leukemia Are Associated with Later Development of Chronic GvHD and Relapse. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828562 | PubMed |
| 41373483 | BTLA-Expressing Memory B Cells Are Associated with Belimumab-Induced Improvement in Systemic Lupus Erythematosus. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41373483 | PubMed |
| 40317077 | Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/40317077 | PubMed |
| 39845702 | Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/39845702 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BTLA | 151888 | PubTator's text mining | https://conductscience.org/library/genes/151888 | NCBI Gene |
| CD27 | 939 | PubTator's text mining | https://conductscience.org/library/genes/939 | NCBI Gene |
| TNFRSF14 | 8764 | PubTator's text mining | https://conductscience.org/library/genes/8764 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39768154
GET https://conductscience.org/api/papers/v1/39768154/references?page=2